BACKGROUND: There is extensive evidence that prepregnancy chronic hypertension is associated with a high risk of development of severe hypertension and preeclampsia and birth of small-for-gestationalage neonates. However, previous studies have not reported whether antihypertensive use, blood pressure control, or normalization of blood pressure during early pregnancy influences the rates of these pregnancy complications. OBJECTIVE: The purpose of this study was to stratify women with prepregnancy chronic hypertension according to the use of antihypertensive medications and level of blood pressure control at the first hospital visit during the first trimester of pregnancy and to examine the rates of severe hypertension, preeclampsia, and birth of small-for-gestational-age neonates according to such stratification. STUDY DESIGN: We conducted a prospective study of 586 women with prepregnancy chronic hypertension, in the absence of renal or liver disease, that was booked at a dedicated clinic for the management of hypertension in pregnancy. The patients had singleton pregnancies and were subdivided according to findings in their first visit: group 1 (n¼199), blood pressure <140/90 mm Hg without antihypertensive medication; group 2 (n¼220), blood pressure <140/90 mm Hg with antihypertensive medication; and group 3 (n¼167), systolic blood pressure 140 mm Hg and/or diastolic blood pressure 90 mm Hg, despite antihypertensive medication. In the subsequent management of these pregnancies, our policy was to maintain the blood pressure at 130e140/80e90 mm Hg with the use of antihypertensive medication; antihypertensive drugs were stopped if the blood pressure was persistently <130/80 mm Hg.
C hronic hypertension is found in 1e5% of pregnancies; the frequency increases with age and weight and is higher in black than in white individuals. 1 In most cases, the condition precedes the onset of pregnancy (prepregnancy); in others, the hypertension develops in the first 20 weeks of pregnancy. 2, 3 In chronic hypertension, there is a high risk for the development of severe hypertension or preeclampsia and delivery of small-for-gestational-age (SGA) neonates. 1, [4] [5] [6] [7] [8] [9] Pregnancy is associated with substantial decrease in peripheral resistance (from as early as 5 weeks of gestation), and many women with prepregnancy chronic hypertension therefore will have normalization of their blood pressure (BP), even without the need for antihypertensive medications. 10 Consequently, women with prepregnancy chronic hypertension fall into 3 broad categories in relation to their BP control when they present to the hospital in the first trimester of pregnancy: those with BP <140/90 mm Hg without antihypertensive medication (group 1), those with BP <140/90 mm Hg with antihypertensive medication (group 2) and those with persistent hypertension (systolic BP 140 mm Hg and or diastolic BP 90 mm Hg), despite antihypertensive medication (group 3). However, previous studies that reported on the association between chronic hypertension and development of severe hypertension or preeclampsia and birth of SGA neonates did not distinguished among these 3 groups of women and have not reported whether antihypertensive use, BP control, or normalization of BP during early pregnancy influence the rates of pregnancy complications. [1] [2] [3] [4] [5] [6] [7] Furthermore, many of the previous studies included women with secondary hypertension, such as those with renal disease, thereby introducing bias because renal disease is a significant risk factor for the development of preeclampsia independent of chronic hypertension. 11, 12 The objective of this study was to stratify women with prepregnancy chronic hypertension according to the use of antihypertensive medications and level of BP control at the first hospital visit during the first trimester of pregnancy and to examine the frequency of severe hypertension, preeclampsia, and SGA according to such stratification.
Methods

Study population
This was an analysis of prospectively collected data in the Antenatal Hypertension Clinic at King's College Hospital, London, UK, between January 2011 and January 2016. According to local protocols, pregnant women with prepregnancy hypertension are referred to this clinic from the first trimester for the management of their pregnancy. The first visit includes recording of maternal demographic characteristics; obstetric, medical, and drug history; measurement of maternal weight and height; recording of BP by validated automated devices and in accordance to the recommendations of the American Heart Association 13, 14 ; and assessment of renal and liver function, which includes measurement of 24-hour urine protein and serum creatinine and aspartate transaminase concentration. The frequency of subsequent visits depends on BP control and, at a minimum, is carried out at 11e13 and 20e24 weeks of gestation and 4 weekly visits thereafter until delivery. These visits include measurement of BP, assessment of renal and liver function, urinalysis for proteinuria, and ultrasound examination for fetal anatomy and growth. In the treatment of patients with chronic hypertension, our policy is to maintain the BP at 130e140/ 80e90 mm Hg throughout pregnancy with the use of antihypertensive medication. Antihypertensive drugs are stopped or their dosage is reduced if the BP is <130/80 mm Hg in 2 consecutive visits.
The inclusion criteria for this study was singleton pregnancies with prepregnancy chronic hypertension in the absence of renal or liver disease that presented to the Antenatal Hypertension Clinic at <14 weeks of gestation and that resulted in the live birth or stillbirth of nonmalformed babies at 24 weeks of gestation. We excluded pregnancies with fetal aneuploidies or major anomalies that had been diagnosed either prenatally or in the neonatal period and pregnancies that ended in miscarriage. All data were collected by 2 trained research doctors under the supervision of a senior specialist in Maternal-Fetal Medicine.
The study is part of our routine clinical management; the local Research and Development Committee (King's College Hospital NHS Foundation Trust) and Research Ethics Committee (London-Dulwich, NRES Committee) advised that formal consideration was not required. Data on pregnancy outcomes were collected from the hospital maternity records and the women's general medical practitioners.
Outcome measures
Women with prepregnancy chronic hypertension were stratified into 3 groups according to their BP control at the first visit to the Antenatal Hypertension Clinic. In group 1, the BP was <140/90 mm Hg without antihypertensive medication; in group 2, the BP was BP <140/90 mm Hg with antihypertensive medication, and in group 3, the BP was 140/90 mm Hg, despite antihypertensive medication.
The outcome measures were severe hypertension, preeclampsia, and birth of SGA neonates. Severe hypertension was defined by the presence of systolic BP 160 mm Hg and/or diastolic BP 110 mm Hg. Superimposed preeclampsia was defined according to the International Society for the Study of Hypertension (2014) guidelines by having, in addition to hypertension, at least 1 of the following problems: renal involvement (proteinuria 300 mg/24 h and/or creatinine 90 mmol/L or 1 mg/dL), liver impairment (transaminases >70 IU/L), neurologic complications (eg, eclampsia), thrombocytopenia (platelet count <150,000/mL). 2 In addition, according to gestational age at diagnosis, preeclampsia was subdivided into preterm preeclampsia with onset at <37 weeks of gestation and term preeclampsia with onset at 37 weeks. SGA was defined as birthweight <5th percentile for gestational age. 15 Because the International Society for the Study of Hypertension (2014) guidelines recognize that the inclusion of fetal growth restriction in the definition of preeclampsia is controversial, we present the data on prevalence of SGA separately from those of the maternal features of the disease.
Statistical analysis
Normality of continuous variables was assessed by the Kolmogorov-Smirnov test. Numeric data were expressed as mean (standard deviation) or as median (interquartile range) for normally and nonnormally distributed data, respectively. Differences in maternal and pregnancy characteristics at the first hospital visit and pregnancy outcomes were compared among the 3 groups of prepregnancy chronic hypertension by the analysis of variance or Kruskal-Wallis tests (for numeric parametric or nonparametric data) with the Bonferroni correction for post-hoc analysis. The Chi-square test was performed for categoric variables and for trend when the proportions between groups demonstrated an obvious trend. Multivariate logistic regression analysis was performed to assess the independent contribution of the 3 groups to pregnancy outcomes when we controlled for maternal demographic characteristics.
Statistical analysis was performed with SPSS statistical software (version 22; SPSS Inc, Chicago, IL).
Results
Population characteristics
The study population that satisfied the inclusion criteria comprised 586 women with prepregnancy chronic hypertension. The median gestational age at presentation was 10.0 weeks (interquartile range, 9.1e11.0 weeks). According to BP control at first hospital visit, 199 women were classified as group 1; 220 women were classified as group 2, and Original Research OBSTETRICS ajog.org 167 women were classified as group 3. During the study period, another 104 women with prepregnancy chronic hypertension attended the unit but were excluded from the study because 31 women were at >14 weeks of gestation, 32 women had prepregnancy renal or liver disease, 23 women had a multiple pregnancy, 7 women had major fetal anomalies, 37 women had experienced a miscarriage, and 15 women had incomplete data.
A comparison of maternal characteristics and results of investigations at the first hospital visit in the 3 groups are given in Table 1 . Approximately 95% of patients in groups 2 and 3 were taking 1 antihypertensive drug; approximately 5% were taking 2 drugs. The most commonly used drugs were labetalol (58.4%), methyldopa (28.9%), and slow-release nifedipine (39.3%). In groups 2 and 3, compared with group 1, there was a significantly higher body mass index, incidence of black racial origin, and history of preeclampsia in a previous pregnancy; there were no ajog.org OBSTETRICS Original Research significant differences between groups 2 and 3. There was a significant increase from group 1 to group 3 in systolic and diastolic BP and mean arterial pressure.
Pregnancy outcome
Pregnancy outcome measures in the 3 groups of women with chronic hypertension are compared in Table 2 and Figure 1 . During the course of pregnancy, in 24.5% of the patients in group 2 and in 6.6% of the patients in group 3, the BP remained <140/90 mm Hg, and the antihypertensive drugs were stopped. In group 1, the BP remained <140/90 mm Hg throughout pregnancy without the need for antihypertensive medication in 62.8% of patients. Deterioration in BP that necessitated the use of 2 antihypertensive medications occurred in 40.1% of the women in group 3, 23.6% of the women in group 2, and 5% of the women in group 1.
Parallel to the use of multiple antihypertensive drugs, there was a significant increase from group 1 to group 3 in the incidence of severe hypertension (10.6%, 22.2%, and 52.1%), total preeclampsia (16.6%, 25.0%, and 26.9%), preterm preeclampsia (7.0%, 15.9%, and 20.4%), and SGA with birthweight <5th percentile (13.1%, 17.7%, and 21.1%), but not term preeclampsia (9.5%, 9.1%, and 6.6%).
In the multivariate logistic regression analysis, the risk for severe hypertension, after adjustment for maternal characteristics, was 9-fold higher in group 3 and 2.5-fold higher in group 2 compared with group 1 (Table 3 ). The risks of preeclampsia and SGA in groups 2 and 3 were approximately double those of group 1.
Comment
Principal findings of the study
The findings of this study demonstrate that, in women with prepregnancy chronic hypertension in the firsttrimester of pregnancy, there is a high incidence of severe hypertension (27%), preeclampsia (23%), and SGA with birthweight <5th percentile (17%). The study also has shown that the incidence of severe hypertension, preterm preeclampsia, and SGA is related to the use of antihypertensive medications and level of BP control in the first trimester of pregnancy; the respective incidences increased from 11%, 7%, and 13% in those women with BP <140/90 mm Hg without the need of taking antihypertensive drugs to 22%, 16%, and 18%% in those women with BP <140/90 mm Hg after the use of antihypertensive drugs and 52%, 20%, and 21% in those women with BP 140/90 mm Hg despite use of antihypertensive drugs.
A likely explanation for our findings is that the 3 subgroups of women with prepregnancy chronic hypertension represent 3 hemodynamic profiles at different stages of the disease. Studies in nonpregnant individuals have Original Research OBSTETRICS ajog.org demonstrated that, in the progression from normal BP to mild and then severe hypertension, there is increasing impairment in endothelial function that ultimately results in structural remodeling of small arterial resistance vessels and leads to relative thickening of the muscular media, vasoconstriction, and decreased capacity for vasodilation. [16] [17] [18] [19] In normal pregnancy, there is early vasodilatation and a decrease in peripheral resistance followed by a compensatory increase in blood volume and cardiac output. 10 We postulate that prepregnancy chronic hypertension in group 1 represents the early phase of chronic hypertension with mild impairment in endothelial function and the consequent ability to achieve the physiologic adaptation to early pregnancy with normalization in BP. 18, 19 However, this group, compared with nonchronic hypertension pregnancies, is still at considerably higher risk for the subsequent development of severe hypertension and preeclampsia. In group 2, there may be moderate endothelial dysfunction the prevents sufficient early vasodilation to achieve normalization in BP; however, the condition is not so severe as to be nonresponsive to antihypertensive drugs. Group 3 may represent severe disease with remodeling of small arteries and decreased capacity for response to antihypertensive drugs; such impairment might also predispose to the subsequent development of preeclampsia and SGA. 18, 19 Preeclampsia, particularly preterm preeclampsia, is associated with an increased risk of subsequent maternal cardiovascular disease. [20] [21] [22] In the context of chronic hypertension, the cardiovascular disease precedes the onset of pregnancy, and the link with preeclampsia may be a similar vascular pathologic disease to atherosclerosis; preterm preeclampsia is characterized by acute atherosis in the spiral arteries in the basal plate of the placenta. 23 
Strengths and limitations of the study
The strengths of this study are (1) prospective examination of a large population of pregnancies with prepregnancy chronic hypertension in the first trimester, (2) exclusion of women with evidence of renal disease, because this is a risk factor for the development of preeclampsia independent of chronic hypertension, (3) accurate recording of medical and drug history and the use of a standardized protocol for measurement of BP, (4) a standardized policy for strict control of BP throughout pregnancy, and (5) stratification of patients according to the use of antihypertensive medications and level of BP control at the first hospital visit and a report of rates of severe hypertension, preeclampsia, and SGA according to such stratification.
We were not able to undertake placental examination to substantiate our hypothesis that preexisting endothelial dysfunction leads to placental dysfunction. Another limitation of the study is the lack of long-term postnatal data regarding the severity of chronic hypertension.
Comparison with findings of other studies
The association of chronic hypertension with severe hypertension, preeclampsia, and SGA has been reported previously but not according to findings in the first trimester. [1] [2] [3] [4] [5] [6] [7] In a study of 109,932 singleton pregnancies in our population who attended for routine pregnancy care at 11e13 weeks of gestation, the overall incidence of preeclampsia was 2.3%; in the subgroup of women with prepregnancy chronic hypertension, the incidence was 20.6%. After adjustment for potential confounding variables from maternal characteristics and medical and obstetric history, the incidence of both preterm and term preeclampsia in women with chronic hypertension was 5e6 times higher than in women without chronic hypertension. 1 
Implications of the findings on clinical practice and future research
Our study has highlighted that, in women with prepregnancy chronic hypertension, there is a high-risk of severe hypertension, preeclampsia, and SGA, despite a policy of that aimed to maintain the BP at 130e140/80e90 mm Hg throughout pregnancy. It is uncertain 
Pregnancy complications in women with prepregnancy chronic hypertension
Rates of severe hypertension, preterm preeclampsia, and small-for-gestational-age baby in the three subgroups of chronic hypertensive women. In nonpregnant individuals with hypertension, there is evidence that the target BP should be very low, because the risk of cardiovascular disease increases with increasing systolic BP at >115 mm Hg 24 ; a large trial demonstrated that intensive treatment that aimed to maintain the systolic BP at <120 mm Hg, as compared with <140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular. 25 In pregnancy, there is reluctance to recommend therapy in mild-to-moderate disease because reduction in BP or the drugs themselves may have an adverse effect on fetal growth. 26, 27 Consequently, the American College of Obstetricians and Gynecologists recommends that pregnancies of women with chronic hypertension treatment should be initiated only if the systolic BP is 160 mm Hg and the diastolic BP is 105 mm Hg. 3, 28 However, in these metaanalyses, most patients had gestational hypertension, rather than chronic hypertension; in most studies, therapy was initiated in the late second or early third trimester. 26, 27 A trial in women with mild chronic hypertension at 6e13 weeks of gestation reported no difference in the risk of preeclampsia or SGA between a policy of antihypertensive treatment and a policy of no treatment. 29 A recent trial of women with chronic hypertension or gestational hypertension and diastolic BP of 90e105 mm Hg at a median gestational age of 24 weeks (range, 14-33 weeks) compared a policy of tight control in BP with a target diastolic BP of 85 mm Hg with a policy of less tight control with target diastolic BP of 100 mm Hg; development of severe hypertension was lower in the tight-control group (28% vs 41%), but there was no significant difference between the 2 policies in the incidence of preeclampsia or SGA. 30 Alternative strategies in the management of prepregnancy chronic hypertension in the first-trimester that are aimed at a reduction of the risk of preeclampsia and SGA include the prophylactic use of aspirin, pravastatin, or metformin. In the Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia (ASPRE) trial, which reported that aspirin (150 mg/ day) from 11e14 to 36 weeks of gestation in pregnancies at high risk for preeclampsia was associated with >60% reduction in the incidence of preterm preeclampsia, the beneficial effect of aspirin did not apply in pregnancies with chronic hypertension. 31, 32 However, there is some evidence that statins and metformin, which inhibit secretion of the angiogenic factor soluble Fms-like tyrosine kinase-1 and decrease markers of endothelial dysfunction and inflammation, may reduce the rate of preeclampsia. [33] [34] [35] [36] [37] Future trials that will investigate the potential value of such medications in patients with prepregnancy chronic hypertension should stratify the population according to the approach proposed in this study because the effect of the drugs is likely to vary according to the severity of the underlying disease.
Conclusions
In women with prepregnancy chronic hypertension, there is a high risk of severe hypertension, preeclampsia, and SGA; the incidence of these complications is related to the use of antihypertensive medications and level of BP control at presentation in the first trimester of pregnancy. n
